Working… Menu

A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS) (CASPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01337401
Recruitment Status : Active, not recruiting
First Posted : April 18, 2011
Last Update Posted : January 24, 2019
Royal Marsden NHS Foundation Trust
Information provided by (Responsible Party):
Institute of Cancer Research, United Kingdom

Brief Summary:

The study is a two-arm, randomised, double-blind, international, multi-centre phase II trial of cediranib in Alveolar Soft Part Sarcoma (ASPS).

The study aims to confirm the ability of cediranib to halt disease progression in patients with metastatic ASPS, as measured by the change in tumour size at 24 weeks after randomisation, and to produce objective response according to RECIST criteria.

Condition or disease Intervention/treatment Phase
Alveolar Soft-part Sarcoma Drug: Cediranib Drug: Placebo Phase 2

Detailed Description:
Patients aged 16 years and older with a histologically confirmed diagnosis of ASPS will be recruited. Eligible patients will be randomised to receive cediranib (30 mg daily po) or placebo (30 mg daily po) in a 2:1 ratio. At 24 weeks post randomisation, treatment will be unblinded after which time all patients on placebo and those who have not progressed on active treatment will be given cediranib. Treatment will then continue until objective disease progression or death.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)
Actual Study Start Date : July 2011
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : January 2020

Arm Intervention/treatment
Experimental: Blinded Cediranib Drug: Cediranib
30mg once daily, oral until disease progression

Placebo Comparator: Blinded Placebo Drug: Placebo
30mg, once daily, oral until 24 weeks or disease progression if sooner

Primary Outcome Measures :
  1. To evaluate the efficacy of cediranib in the treatment of ASPS by measuring the percentage change in the sum of target marker lesion diameters from randomisation to week 24 (or progression if sooner) compared to treatment with placebo. [ Time Frame: 24 Weeks of treatment ]

Secondary Outcome Measures :
  1. Response rate at week 24, best response using RECISTv1.1 and best reduction (%) in tumour size [ Time Frame: 24 Weeks of treatment ]
  2. Progression-free survival and percentage alive and progression-free at 12 months (APF12) [ Time Frame: 12 months of treatment ]
  3. Length of Overall survival [ Time Frame: Patients will be followed up every 12 weeks ]
  4. The safety and tolerability profile of cediranib in patients with ASPS [ Time Frame: Assessments will be made at every study visit (8-12 weekly) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed diagnosis of ASPS (central confirmation not required at study entry)
  2. Age 16 years and older
  3. Availability of archived tissue blocks or unstained slides to enable confirmation of t(X;17) translocation
  4. ECOG Performance Status of 0-1
  5. Life expectancy of >12 weeks
  6. Progressive disease as defined by RECIST v1.1 within 6 months prior to randomisation
  7. Measurable metastatic disease using RECISTv1.1, i.e. at least one lesion 10 mm in diameter (15 mm in short axis for nodal lesions) assessable by CT (or MRI for brain metastases).
  8. Patients with brain metastases are permitted provided disease is controlled with a stable dose of corticosteroid and/or non-enzyme inducing anticonvulsant
  9. The capacity to understand the patient information sheet and ability to provide written informed consent
  10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures
  11. Able to swallow and retain oral medication

Exclusion Criteria:

  1. Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count ≤1.5 x 109/L or platelet count ≤100 x 109/L
  2. Serum bilirubin ≥ 1.5 x ULN (unless Gilbert's syndrome)
  3. ALT or AST ≥ 2.5 x ULN. If liver metastases are present, ALT or AST > 5 x ULN
  4. Serum creatinine > 1.5 x ULN or a creatinine clearance (calculated or measured) of ≤ 50mL/min
  5. Greater than +1 proteinuria unless urinary protein < 1.5g in a 24 hr period or protein/creatinine ratio < 1.5.
  6. History of significant gastrointestinal impairment, as judged by the Investigator, that would significantly affect the absorption of cediranib.
  7. Patients with a history of poorly controlled hypertension with resting blood pressure >150/100 mmHg in the presence or absence of a stable regimen of anti-hypertensive therapy.
  8. Any evidence of severe or uncontrolled co-morbidities e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease, or active and uncontrolled infection.
  9. Evidence of prolonged QTc >480 msec (using Bazetts correction, for which the formula is: QTc = QT/√RR) or history of familial long QT syndrome.
  10. Significant recent haemorrhage (>30mL bleeding/episode in previous 3 months) or haemoptysis (>5mL fresh blood in previous 4 weeks).
  11. Major thoracic or abdominal surgery in the 14 days prior to entry into the study, or a surgical incision that is not fully healed.
  12. Pregnant or breast-feeding women; women of childbearing potential with a positive pregnancy test prior to receiving study medication; women the intention of pregnancy during study treatment; women of child bearing potential unwilling to have a urine or serum pregnancy test prior to study entry (even if surgically sterilised).
  13. Men and women of childbearing potential unwilling to use adequate birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilisation) for the duration of the study and should continue such precautions for 2 weeks after receiving the last study treatment.
  14. History of anticancer (including investigational, non-registered) treatment in the four weeks prior to first dose of cediranib, with the exception of palliative radiotherapy for symptom control.
  15. Previous treatment with cediranib.
  16. Known hypersensitivity to any excipient of cediranib.
  17. History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within 5 years, unless the patient has been disease free for 2 years and there is a tissue diagnosis of the primary cancer of interest from a target lesion.
  18. Other concomitant anti-cancer therapy (including LHRH agonists) except steroids
  19. Recent history of thrombosis
  20. Patients with brain metastases if they are symptomatic requiring increasing steroids in the previous six weeks to study entry or those with evidence of recent and/or active bleeding, or those causing uncontrolled seizures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01337401

Layout table for location information
Princess Alexandra Hospital
Brisbane, Australia
Royal Prince Alfred Hospital
Sydney, Australia
Hospital Santa Cruz i Sant Pau
Barcelona, Spain
Hospital Puerta de Hierro
Madrid, Spain
Hospital Miguel Servet
Zaragoza, Spain
United Kingdom
Bristol Haematology and Oncology Centre
Bristol, United Kingdom
Royal Marsden Hospital
London, United Kingdom
University College London Hospital
London, United Kingdom
Christie Hospital
Manchester, United Kingdom
Royal Victoria Infirmary/Freeman Hospital
Newcastle-Upon-Tyne, United Kingdom
Nottingham University Hospitals
Nottingham, United Kingdom
Sponsors and Collaborators
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Institute of Cancer Research, United Kingdom Identifier: NCT01337401     History of Changes
Other Study ID Numbers: ICR-CTSU/2010/10027
2010-021163-33 ( EudraCT Number )
CRUK/10/021 ( Other Grant/Funding Number: Cancer Research UK )
ISRCTN63733470 ( Registry Identifier: Randomised controlled Trials )
ISSRECE0036 ( Other Grant/Funding Number: AstraZeneca )
First Posted: April 18, 2011    Key Record Dates
Last Update Posted: January 24, 2019
Last Verified: January 2019
Keywords provided by Institute of Cancer Research, United Kingdom:
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma, Alveolar Soft Part
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Muscle Tissue
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action